Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension

Tongers, Jörn; Schwerdtfeger, Ben; Klein, Gunnar; Kempf, Tibor; Schaefer, Arnd; Knapp, Julia-Marie; Niehaus, Michael; Korte, Thomas; Hoeper, Marius M.

doi:10.1016/j.ahj.2006.09.008

Cited by 239 publications

(266 citation statements)

References 48 publications

Supporting

Mentioning

222

Contrasting

Unclassified

Order By: Relevance

“…Treatment of atrial flutter proved to be more successful than treatment of atrial fibrillation. Restoration of a stable sinus rhythm was associated with a favourable long-term survival while persistent atrial fibrillation was associated with a 2-yr mortality of .80% [46]. Although prospective and controlled data are lacking, these findings suggest that maintenance of a stable sinus rhythm should be considered an important treatment goal in patients with PAH.…”

Section: Treatment Of Arrhythmiasmentioning

confidence: 90%

“…In a series of 132 witnessed cardiac arrests in patients with PAH, ventricular fibrillation was observed in only 8% of the cases [168]. Another series of 231 patients with PAH or CTEPH followed over a 6-yr period did not report any case of malignant ventricular arrhythmia [46]. In that series, supraventricular tachyarrhythmias occurred with an annual incidence of 2.8%.…”

Section: Treatment Of Arrhythmiasmentioning

confidence: 96%

See 1 more Smart Citation

Guidelines for the diagnosis and treatment of pulmonary hypertension

Galiè¹,

Hoeper²,

Humbert³

et al. 2012

Revista Portuguesa de Cardiologia (English Edition)

Self Cite

418

738

View full text Add to dashboard Cite

Section: Treatment Of Arrhythmiasmentioning

confidence: 90%

Section: Treatment Of Arrhythmiasmentioning

confidence: 96%

Guidelines for the diagnosis and treatment of pulmonary hypertension

Galiè¹,

Hoeper²,

Humbert³

et al. 2012

Revista Portuguesa de Cardiologia (English Edition)

Self Cite

418

738

View full text Add to dashboard Cite

“…13 Two of the women (B and D) experienced sustained arrhythmia and of these one died. Data from non-pregnant women with PH suggest that sustained atrial arrhythmias 14 The additional volume load and haemodynamic stress imposed by pregnancy on the already pressure-overloaded right heart may increase the tendency for both atrial and ventricular arrhythmia. This has previously been reported in other congenital lesions, where right ventricular dilatation has been shown to be associated with a higher incidence of arrhythmia.…”

Section: Predictors Of Outcomementioning

confidence: 99%

Pulmonary hypertension and pregnancy—a review of 12 pregnancies in nine women

Curry

Fletcher

Gelson

et al. 2012

BJOG

View full text Add to dashboard Cite

Objective To report outcomes in a recent series of pregnancies in women with pulmonary hypertension (PH).Design Retrospective case note review. Setting Tertiary referral unit (Chelsea and Westminster and Royal Brompton Hospitals).Sample Twelve pregnancies in nine women with PH between 1995 and 2010.Methods Multidisciplinary review of case records.Main outcome measures Maternal and neonatal mortality and morbidity.Results There were two maternal deaths (1995 and 1998), one related to pre-eclampsia and one to arrhythmia. Maternal morbidity included postpartum haemorrhage (five cases), and one post-caesarean evacuation of a wound haematoma. There were no perinatal deaths, nine live births and three first-trimester miscarriages. Mean birthweight was 2197 g, mean gestational age was 34 weeks (range 26-39), and mean birthweight centile was 36 (range 5-60). Five babies required admission to the neonatal intensive care unit, but were all eventually discharged home. All women were delivered by caesarean section (seven elective and two emergency deliveries), under general anaesthetic except for one emergency and one elective caesarean performed under regional block.Conclusions Maternal and fetal outcomes for women with PH may be improving. However, the risk of maternal mortality remains significant, so that early and effective counselling about contraceptive options and pregnancy risks should continue to play a major role in the management of such women when they reach reproductive maturity.

show abstract

“…Moreover, patients may be stable and even exhibit a good functional capacity for years with persistently elevated pulmonary artery pressures and a chronically impaired right ventricle, yet still succumb to "late" disease progression or become vulnerable to acute insults, such as sepsis, 15,16 pulmonary embolism, 17 and arrhythmias. 18 As a result, patients with PAH still warrant vigilant and systematic monitoring of their condition. To further improve outcomes and advance the field, not only are new therapeutic agents needed, but study designs and end points need to be redefined, particularly the primary end Figure 1.…”

Section: Contemporary Outcomes With Modern Pah Managementmentioning

confidence: 99%

From Short‐Term Benefits to Long‐Term Outcomes: The Evolution of Clinical Trials in Pulmonary Arterial Hypertension

Chakinala

Barst

2013

Pulm. circ.

View full text Add to dashboard Cite

Over the past 2 decades, major advances in our understanding of pulmonary arterial hypertension (PAH) have led to the development of new targeted therapeutics and management strategies that have provided benefits to patients with this devastating disease. Despite such improvements, no therapies are curative, and PAH remains a progressive disease associated with high morbidity and suboptimal survival in many patients. Clinical research in PAH is currently at a crossroads. To move forward, not only are new therapies needed, but novel approaches to clinical trial design are also required. Trials should be designed to assess the longer-term benefits of investigational therapies in what has become a chronic disease. Moreover, there is a need to consider moving away from short-term trials that use markers such as the 6-minute walk distance as a measure of exercise capacity as primary end points to longer-term, event-driven trials with composite end points made up of clinically relevant measures that better reflect the ultimate goals of reducing morbidity and mortality. A shift in trial design may also be useful in overcoming some of the muted results from recent pivotal phase III studies of combination therapy by allowing the potential of these regimens to be more comprehensively assessed.

show abstract

Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension

Cited by 239 publications

References 48 publications

Guidelines for the diagnosis and treatment of pulmonary hypertension

Guidelines for the diagnosis and treatment of pulmonary hypertension

Pulmonary hypertension and pregnancy—a review of 12 pregnancies in nine women

From Short‐Term Benefits to Long‐Term Outcomes: The Evolution of Clinical Trials in Pulmonary Arterial Hypertension

Contact Info

Product

Resources

About